nintedanib

Nintedanib (Intedanib) is a triple vascular kinase inhibitor that inhibits VEGFR1, VEGFR2, and VEGFR3 (IC50=34 13 13 nM), FGFR1, FGFR2, and FGFR3 (IC50=69 37 108 nM), PDGFRα, and PDGFRβ (IC50=59 65 nM). Nintedanib has antitumor activity and inhibits tumor growth by inhibiting angiogenesis.

Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor targeting VEGFR1 2 3, FGFR1 2 3, and PDGFRα β.

Nintedanib esylate hemihydrate is a potent inhibitor of multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs).

Nintedanib-13C-d3 is the 13C and deuterated compound of Nintedanib. Nintedanib has a CAS number of 656247-17-5. Nintedanib is an inhibitor of the receptor tyrosine kinases VEGFR FGFR PDGFR (IC50s: 13-34 37-610 59 65 nM for VEGFR1-3, FGFR1-4, and PDGFRα β, respectively).

Nintedanib-d8 is a deuterated compound of Nintedanib. Nintedanib has a CAS number of 656247-17-5. Nintedanib is an inhibitor of the receptor tyrosine kinases VEGFR FGFR PDGFR (IC50s: 13-34 37-610 59 65 nM for VEGFR1-3, FGFR1-4, and PDGFRα β, respectively).

MELK-IN-1 (MELK inhibitor 17) is a potent inhibitor of maternal embryonic leucine zipper kinase (MELK),(IC50:3nm;Ki:0.39 nM).